Please login to the form below

Not currently logged in
Email:
Password:

Merck to launch Tredaptive internationally

Merck is to commence the launch of its cholesterol drug, Tredaptive in international markets by Q3 2009

Merck is to commence the launch of its cholesterol drug, Tredaptive in international markets by Q3 2009.

Tredaptive (also known as Cordaptive) is a therapy for patients with mixed dyslipidemia and primary hypercholesterolemia. It has been licensed in the EU for use in combination with statins or as a monotherapy when statins are inappropriate.

It is approved for use in 39 countries outside of the US. The FDA refused to approve the drug for use in the US until more supporting evidence was available.

"Merck is pleased that we are now able to supply Tredaptive in approved markets and continue our long-standing commitment to help address unmet medical needs in cardiovascular care," said Dr Luciano Rossetti, senior vice president and franchise head, atherosclerosis and cardiovascular, Merck Research Laboratories.

19th May 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics